Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...

Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) ...

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...

A new study found that people taking Wegovy during the pandemic were 33 percent less likely to die of COVID-19.

The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise ...

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

While Ozempic and similar medications are all the buzz right now, many of us still aren’t sure what they actually are or how they work! This video breaks down all the essential details to help you ...

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

These drugs work to treat diabetes and weight loss by suppressing the appetite and lowering blood sugar and A1C—which may end ...

A recent study estimated that Wegovy’s label expansion beyond obesity could push Medicare spending to $145 billion annually, ...